<DOC>
	<DOCNO>NCT02320812</DOCNO>
	<brief_summary>This study evaluate safety potential activity single dose live human retinal progenitor cell ( jCell ) administer adult retinitis pigmentosa . Two different dose level cell assess two group patient .</brief_summary>
	<brief_title>Safety Single , Intravitreal Injection Human Retinal Progenitor Cells ( jCell ) Retinitis Pigmentosa</brief_title>
	<detailed_description>The primary purpose study test safety tolerability administration single dose jCell adult retinitis pigmentosa . The goal jCell therapy preserve vision intervene disease time host photoreceptors protect potentially reactivate . Human allogeneic retinal progenitor cell inject adult advance RP see procedure safe , cell survive , whether impact visual status patient .</detailed_description>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<criteria>Clinical diagnosis RP confirm ERG willing consent mutation typing , already do Best correct visual acuity ( BCVA ) 20/63 bad bad HM ( hand motion ) Adequate organ function negative infectious disease screen Female childbearing potential must negative pregnancy test willing use medically accept method contraception throughout study Eye disease RP impair visual function PseudoRP , cancerassociated retinopathy History malignancy endstage organ disease , chronic disease require continuous treatment system steroid , anticoagulant immunosuppressive agent Known allergy penicillin streptomycin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>